Navigation Links
Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors
Date:8/17/2009

PALO ALTO, Calif., Aug. 17, 2009 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies with a focus on the NS4B Hepatitis C Virus (HCV) protein, announced today the appointment of Paul Truex to its Board of Directors.

Truex is the founder, President and CEO of Anthera Pharmaceuticals - a private pharmaceutical company focused on the development of anti-inflammatory products for life threatening cardiovascular and pulmonary diseases. Previously' he was Founder, President and CEO of Peninsula Pharmaceuticals where he negotiated both of Peninsula's anti-infective product agreements with Shionogi & Co.' Ltd. and Takeda Chemical Industries respectively. Peninsula was acquired by Johnson & Johnson in 2005 for $245 million. Previously, Mr. Truex held positions at Versicor (Vicuron), which was acquired by Pfizer for $1.9 billion, and at Eli Lilly. Mr. Truex obtained his M.B.A. in Marketing and Finance from Indiana University and a B.A. Degree in International Economics from the University of Waterloo.


"We are delighted to have Mr. Truex join Eiger's Board as an Independent Director," said David Cory, President and CEO of Eiger. "Paul will bring valuable experience to our corporate strategy and development as we advance both preclinical and clinical programs at Eiger."

"The combination of newly discovered HCV targets along with clinical and preclinical small molecule inhibitors already identified by Eiger make this a very exciting opportunity in the infectious disease space," said Paul Truex. "I'm looking forward to working with the Eiger board and management team to build a successful company."

Eiger BioPharmaceuticals recently announced the acquisition of exclusive license to novel HCV technology discovered in the labs of Stanford scientist and Eiger Founder Dr. Jeffrey Glenn, MD, PhD. This technology targets a specific region found in the HCV protein NS4B, which binds to HCV-RNA and is required for virus replication. Disrupting the function of this protein provides for a new method to treat HCV infection and can help combat drug resistance to HCV polymerase and protease inhibitors.

About Eiger BioPharmaceuticals, Inc. www.eigerbio.com

Eiger is focused on the discovery and development of new antiviral agents against novel targets for the treatment of hepatitis virus infection. Eiger's pipeline includes repurposed clinical stage therapeutic agents as well as NCEs from discovery that exhibit antiviral activity against Hepatitis C, Hepatitis D, and other viruses. Eiger investors include InterWest Partners www.interwest.com and Vivo Ventures www.vivoventures.com.

    Contact:
    1-650-320-9900
    info@eigerbio.com


'/>"/>
SOURCE Eiger BioPharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors
2. Eiger BioPharmaceuticals Raises $7.1 Million A Round
3. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
8. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
9. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
10. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
11. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... N.C. , Feb. 5, 2016  In the ... role for a host of launch activities including the ... of this launch activity is especially high in the ... Best Practices and the Role of Medical ... help companies focused on oncology therapies find better ways ...
(Date:2/5/2016)... 5, 2016 Australian-US drug discovery and development company, ... appointment of a new Chairman, Mr John O,Connor , ... immediately. James Garner , has also been ... former Acting CEO, Mr Iain Ross , will resume ... --> James Garner , has also been formally appointed ...
(Date:2/4/2016)... RICHMOND, Calif. , Feb. 4, 2016  Sangamo ... therapeutic genome editing, announced today that Edward Lanphier ... an update on the progress of Sangamo,s ZFP Therapeutic ... company,s business strategy at 2:40 pm ET on Thursday, ... Annual Global Healthcare Conference. The conference is being ...
(Date:2/4/2016)... 4, 2016 Beike Biotechnology, the ... attended a ceremony in late 2015 to mark their ... in 2016. --> --> ... for Personalized Cell Therapy" was hosted by the Shenzhen ... both subsidiaries of Beike Biotechnology Co., Ltd. ...
Breaking Biology Technology:
(Date:2/1/2016)... -- Today, the first day of American Heart Month, the ... first of its kind workplace health solution that leverages ... first application of Watson to ... Welltok will create a new offering that combines AHA,s ... on Welltok,s health optimization platform. The effort is intended ...
(Date:1/25/2016)... BELL, Pa. , Jan. 25, 2016   Unisys Corporation ... recognition system at John F. Kennedy (JFK) International Airport, ... Border Protection (CBP) identify imposters attempting to enter ... do not belong to them. pilot testing of ... out initially at three terminals at JFK during January 2016. ...
(Date:1/21/2016)... January 21, 2016 ... new market research report "Emotion Detection and Recognition Market by ... Tools (Facial Expression, Voice Recognition and Others), Services, ... forecast to 2020", published by MarketsandMarkets, the global ... reach USD 22.65 Billion by 2020, at a ...
Breaking Biology News(10 mins):